opportun upgrad
rais estim driven counsyl integr
hct stabil pt upgrad ow improv
test uptak reimburs entri fast grow
prenat test via counsyl opex cut next
upgrad overweight equal-weight believ
earn profil dramat chang observ core hct
busi show durabl bear give credit volum return
growth price declin slow outlin march upgrad
equal-weight balanc risk/reward hct share improv upgrad
ew acquisit expand compani
psychiatri assurex natur leverag point core obgyn busi
pre-nat counsyl also diversifi higher growth improv asp
test market conserv estim make appear inexpens
one highest nomin yield space despit
grow nomin ahead peer ebit estim
move higher consensu similar degre
improv stabil see core hct inclus counsyl
believ buysid also yet incorpor dynam
view stock catalyst annual guidanc includ counsyl
expect earn august expect drive consensu
estim higher rais pt base dcf
impli yield ep peer trade
despit grow faster next year
risk noteworthi model leav margin error note
bear correct limit visibl pace
genesight reimburs counsyl share trend hereditari cancer/hct
price trend took conserv view point build
life scienc tool diagnost unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
updat forecast genesight asp trend assum less half
payor reimburs target level far spite support clinic
cost-benefit data counsyl assum share trend hold
acceler acquisit compani even sale forc
larger also assum market growth upsid medicaid
potenti coverag expans averag risk see detail acog chang
averag risk coverag upsid driver jul hct assum
price continu declin per year detail assumpt
bull bear scenario page
rais estim hct price addit counsyl
rais estim higher hct price inclus counsyl
counsyl assum share gain hold steadi per year near-
term disrupt merger integr assum cogs/test test
declin recent trend
cost program drive legaci counsyl gross margin
elev alreadi quarter ahead schedul look
conserv see overal rais ep estim
drive pt base dcf impli
ep current multipl
chang price target base modif
dcf valuat revis way consid amort recent
acquisit off-set minor adjust lower free cash flow
current yield chang reflect page report
origin publish juli republish juli
price data disclosur reflect origin public date receiv electron
copi origin version public pleas send email
public titl
price target reflect dcf valuat util base case
forecast wacc termin growth rate
impli ep current multipl
bull case ep
bull case ep
price stabl hct gain share genesight
receiv signific increment payor coverag post-publ peer-
review data includ major payor unit drive
counsyl share gain acceler via salesforc scale tradit
pace integr year vectra acr guidelin could drive
greater volum price multipl expand histor peak
base case ep
base case ep
myriad see modest price declin hct continu
declin market share loss slow genesight receiv modest
increment payor coverag reach counsyl
share gain remain pace integr salesforc
remain pace increment cost save
mutlipl contract averag
bear case ep
bear case ep
price declin hct acceler myrisk get recod
cms/oig volum declin genesight receiv littl
increment payor coverag counsyl share gain slow histor pace post-
integr run area remov cost multipl
contract histor trough
myriad sole
provid mutat
screen test key patent
invalid suprem court new
entrant made market
myriad sought off-set share
price pressur core brca franchis
diversifi product portfolio test
ra prostat cancer depress
recent pre-nat counsyl
focus cost disciplin
clinician sticki slower public
databas buildout lead less signific
market share loss price drop myrisk
uptak test high-risk breast cancer
ovarian cancer colorect cancer patient
vectra prolari genesight growth
volum asp secur privat payer
share gain pre-nat
year
risk achiev price
slower penetr breast ovarian
lack payor coverag genesight
medicar code myrisk well
current price
upgrad overweight
benefit scale diversif diversifi away histor
relianc high-margin hereditari cancer test hct pressur
toward psychiatri prenat test penetr low price stabl
improv expect assurex/counsyl drive half ebit point
hct drive earn power exhibit structur believ
among best-posit player molecular test larg sale forc
effici lab oper driven compani lead scale advantag allow
drive substanti commerci effort rel competitor
deliv new test develop new market without incur loss larg
peer without scale advantag
chang importantli core hct busi stabil volum growth
improv price trend hct busi drag ep
addit new test acquir assurex counsyl
acquisit psychiatr drug prescript guidanc prenat test grow
drive half ebit model counsyl deal ideal fit
signific revenu synergi lead women health genom
salesforc oper leverag drive ep accret
see price underli basi ex-counsyl ep
ahead consensu contribut counsyl hereditari volum move
myrisk higher reimburs drive accret pro-forma
ep overal rais ep estim exhibit driven
counsyl improv hct stabil
exhibit bridg prior current revenu ebit estim driven myrisk
exhibit chang forecast
thomson reuter data research estim
sale
sale
sale
sale
note chang larg driven interest incom treatment
detail counsyl revenu synergi opportun counsyl acquisit close
expect summer offer suit product pre-nat test market
estim total grow counsyl share carrier screen
market within pre-nat share nipt gain larger competitor includ
lh roch sinc core obgyn custom base prenat
test mygn strongest custom concentr hct present revenu
cost synergi opportun combin counsyl plu offer top tier
bundl test opportun obgyn custom line-up match
lh/dgx cover ricki goldwass unmatch
commercial/contracting/logist team see first take deal plenti upsid
entri prenat may includ obgyn sale forc
size largest comp see rapid accret ep
inexpens stock view base forecast pro-forma
counsyl trade yield compar median
yield tools/dx comp reflect under-appreci drop-through
achiev increment reimburs genesight prolari opex
reduct said see grow nomin compound-annual-growth-rate
faster peer group period make attract
entri point view exhibit compar coverag nomin
make adjust acquisit given limit visibl acquisit
contribut level balanc sheet uncertainti given
major tools/dx/dent coverag highli acquisit see
gener next year estim take share vs
exhibit cheapest stock coverag term
thomson reuter data morgan stanley research
exhibit look cheap price-to-earnings vs ep growth
thomson reuter data morgan stanley research
see hct trend improv volum acceler sinc mid riskscor
drove gain prevent competit genet counselor channel becam
smaller piec mix compet lab qualiti challeng made share gain faster
price declin moder post drag mid renew
lock year spite price pressur pama conserv
assum reach roughli stack
paid today breast/ovarian panel pan-canc limit
downsid visibl oig/hh subpoena look price
bear remain focus oig palmetto/nordian local medicare/aid contractor
potenti requir myrisk code volum total
drive price lower hct medicare/aid likelihood signific
price declin among privat payor contract laps view
oig inquiri resolut like benign recal settlement
genesight still biggest upsid risk genesight could drive increment
ep assess genesight catalyst depth genesight path
reimburs clearer post pivot clinic trial data last may
posit payor decis prior journal public genesight cost/benefit analysi
clinic data shown date suggest bear case scenario double-digit volum growth
modest/gradu asp uptrend new news genesight bull scenario
ep insur cover test turn posit list price
peer-review cost analys would support assumpt
progress slower given visibl coverag process impli
ebit ep
see fundament stabil hereditari margin mostli hold
cog effici product margin ramp behind coverag asp
improv busi mix remain significantli reliant hereditari
cancer test exhibit see evolv new product genesight
prolari see benefit asp improv behind growth insur coverag
remain risk medicar coverag vectra repres almost
vectra coverag today paid pama lcd review
palmetto draft non-coverag decis decemb time medicar
continu pay claim point possibl medicar make chang
prior coverag visibl situat may resolv
exhibit revenu mix evolv away hereditari cancer declin yet
product see grow greater insur coverag time
margin converg across platform time importantli margin appear
stabil behind cog improv hereditari busi assurex
see benefit scale meanwhil see new product ramp lead
strong ramp expect margin busi exhibit
expect hereditari gross margin product behind
ramp continu cog improv margin begin converg
busi drive underli stabil
exhibit expect gross profit mix tilt favor product outsid hereditari cancer
insur coverag ramp product lead improv hereditari gm
remain steadier impli due cog effici
chang underli opex pictur elev cost program
track increment cost take-out anoth
plan total roughli in-lin model see
organ opex shrink behind greater oper
leverag synergist deal counsyl remov cost
underli run-rat ebit line expect elev cost
reduct program take anoth underli oper expens drive ebit
growth vs last year note ebit margin reach
model believ conserv given esoter mix vs
larg lab lh ebit margin
exhibit organ opex bridg ex-m suggest opex continu declin behind elev
adjust oper expens
y/i growth organ opex
y/i organic-organ chg margin
frame bull-bear scenario risk bull case valuat impli meaning
genesight reimburs stabl hct price drive stock base
multipl bear case impli increment genesight reimburs mid-teen
hct declin drive stock base trough multipl
price hct manag call stabl price forecast
declin could prove conserv given suggest
privat payor contract fix
bracanalysi cdx metastat breast cancer volum guidanc assum
follow similar uptak curv ovarian cancer despit preval
pool stronger salesforc presenc commun oncologist offic
genesight receiv increment payor coverag post-publ peer-review
data estim out-year price asps/test assum
payor coverag target price
counsyl share gain acceler via salesforc scale tradit pace
vectra acr guidelin could drive greater volum price
hct price noridian requir myrisk code decreas vs
current code though see unlik near-term visibl
genesight may receiv increment payor coverag remain
elev may abl continu find cost-cut
opex assumpt assum continu msd growth ex-elev believ
vectra ncd neg pull back coverag
compani data morgan stanley research
trade yield compar median yield
tools/dx comp reflect under-appreci drop-through
achiev increment reimburs genesight prolari opex reduct
said see grow compound-annual-growth-rate faster
peer group period pt impli trade
ep current price-to-earnings multipl trail averag
price target reflect dcf valuat util base case forecast
wacc termin growth rate impli ep
risk price target includ market share loss price drop myrisk weaker
penetr breast ovarian colorect cancer asymptomat market code risk
adopt myrisk genesight receiv less privat insur coverag
dollar million except per share data
 increas work capit
present valu free flow
pv free flow
pv termin valu
equiti valu month today
weight averag debt equiti capit wacc
equiti
margin debt
after-tax debt
weight averag capit
annual chang ebit margin
depreci revenu
capit expenditur revenu
stock comp revenu
chang work capit revenu
myrisk franchis
myrisk franchis
myrisk franchis
myrisk franchis
myrisk franchis
total revenu
total revenu
total revenu
total revenu
total revenu
total revenu
total revenu
total revenu
total revenu
total revenu
total revenu
total revenu
total revenu
